




Urgent Management of TIA

PROF. A. HAQUE *FCPS, FRCR(E), PhD*



Chairman, Neurology, Bangabandhu Sheikh
Mujib Medical University, Dhaka

Urgent management of TIA & minor stroke



- Is urgent management effective?
- Evidence for urgent management
- Is urgent management safe?
- Questions



SOS TIA: results



- Mean age 62 years old, 51% male
- 53% of patients seen on same day as TIA
- 26% admitted

- 13 strokes at 90 days
- 90-day stroke rate- 1.2% (95% CI 0.7–2.1) vs 6.0% predicted by ABCD² score

Cumulative risk of stroke after TIA: OXVASC & OCSP



ABCD score

A: age = 1 in **≥ 60 yrs**


B: BP = 1 for > 90 D.

C: C/F = 2 for focal weakness
1 for speech problem


D: Symptom duration = 1 for < 59
min

2 for **≥ 60 min**

* Score 6 high risk : $< 4 = 0\%$ $> 4 = 35\%$



Definition of Stroke



- Stroke (Brain attack) is a syndrome characterized by rapidly developing clinical symptom/or sign of focal loss(sometimes global) of cerebral function in which symptom lasts >24 hours or leads to death where no apparent cause other than vascular origin
- TIA: Same symptoms but lasting for <24 hours.


Etiological classification-1

- ISCHAEMIC


Cardioembolic: AF, mural thrombus, paradoxical embolism from PFO, endocarditis

Atherothromboembolic: carotid atheroma, vertebral atheroma, cerebral a occlusion, carotid dissection

Small vessel disease: hypertensive vasculopathy, diabetic vasculopathy, vasculitis



Etiological classification-2



- **Others**

 - venous sinus thrombosis

 - Unknown**


- **HAEMORRHAGIC**


 - Subarachnoid:** AVM, Aneurysm

 - Parenchymal haemorrhage:**
hypertensive, amyloid

Clinical classification


- Total anterior circulation stroke(TACS)
- Partial anterior circulation stroke(PACS)
- Lacunar stroke
- Posterior circulation stroke(POCS)





Major Pathways of cell death

- ✧ Excitotoxicity
- ✧ Oxidative stress
- ✧ Apoptosis




How neurone die after stroke



⌘ Not all cell die immediately

⌘ Cell death evolve slowly in heterogenous area- penumbra *Sharp, 2000.*



⌘ Penumbra is electrically silent

⌘ Metabolically active to sustain membrane potential

⌘ Precise timing & mechanism ?

↓ O₂ & glucose



↓ ATP



Ionic gradient loss



Glutamate release & re-uptake impaired
Binds to receptor → promotes Ca⁺⁺ entry & release



Ca⁺⁺ dependent synthases impaired



Degrade Cyto-skeletal & enzymatic protein
Generate NO, ONOO⁻



Mitochondrial function fail



Reactive O^o release



Attack protein, lipid, nucleic acid



Release families of executioner molecule (caspases, AIF)



Dismantle cytoplasm & nucleus




Promote apoptosis



History taking


- Sudden numbness/weakness of face, arm, leg sp. One side
- Sudden confusion, speech/understanding
- Sudden deterioration of vision-one/both
- Sudden difficulty in walking/dizziness/balance/co-ordination
- Sudden severe headache with no cause



Clinical Examination:

(best done using Leeds Stroke Clerking proforma)


1. General examination
2. GCS
3. Communication difficulty
4. Examine cranial nerves
5. Assess for swallowing difficulties using test swallow
6. Examine limbs for tone, power, sensation, reflexes




Investigation in A&E:

1. FBC, PV, U&E, GIC
2. ECG
3. Urine analysis Chest X-ray should not be undertaken as a routine investigation at admission unless symptoms specifically indicate it, (RCP)
4. CT brain scan, ideally within 24 hours


Brain imaging should be undertaken as a matter of urgency if:



- There is a clinical deterioration in the patient's condition;
- Subarachnoid haemorrhage is suspected;
- Hydrocephalus secondary to intracerebral haemorrhage is suspected;
- Trauma is suspected;
- The patient is on anticoagulant treatment, or has a known bleeding tendency;
- The diagnosis is in doubt because of other unusual features.



Treatment




- Premedical care
- NINDS recommendations for thrombolysis
- Door to doctor 10mins
- Access to neurology 15min
- Door to CT 25min
- Door to CT interpretation 45mins
- Door to treatment 60mins
- Admission to monitor bed 3hours



Guideline for TIA

- Timing
- Hospitalization
- Laboratory test
- Echocardiography
- Brain imaging
- Carotid duplex
- Anti coagulation/anti platelet
- CEA



General measures

- DIET


NPO until swallowing is assessed
If risk of aspiration tube or PEG

- ACTIVITY

activity is tailored to the severity of stroke
physical therapy should be started within hours
early mobilisation




Medicines In Stroke



- T-PA (*0.9mg/kg iv; not to exceed 90mg; infuse over 60min with 10% of total dose administered as initial iv bolus over 1min*)
- Antihypertensive
Labetalol, Enalapril, Nicardipine, Sodium nitropruside
- Antiplatelet Aspirin,
- Anticonvulsant Diazepam, Lorazepam,
- Antipyretic Paracetamol

Further inpatient care

- Care is tailored to severity and comorbid illness
- Observe pts condition 25% worsen in 24-48 hr
- facilitate medical and surgical measures to improve outcome eg carotid stenosis, cardioembolic source
- Prevent subacute complication eg LMW heparin, stockings, fluid, electrolyte etc
- Initiate therapy to prevent recurrence
- Begin effort to restore function through rehab
- Treat comorbid condition ziz, DM, Hyperlipidemia, cardiac arrhythmia, hypertension



New therapies

Desmoteplase – Favorable outcome

In Rx 22.0% placebo 13.3% (62.5mg / kg)


46.7% (90mg/kg) = $P = .053$

60% (125mg/kg) $P = 0.009$

Reduction of perfusion lesion volume in MRA was 71.4%


Ximelagatrans- a thrombin inhibitor is better than warferin
because it does not need regular INR check-up.

SPORTIF, 2005




New Rx

- ✧ Mechanical clot removal
 - ✧ The primary endpoint of partial or complete recanalization rate was 53.5% in MERCI 18% in PROACT placebo
- ✧ Endarterectomy >70% in symptomatic
 - ✧ In Asymptomatic – less clear ACAST trial 3120 pt. Over 60% stenosis
- ✧ Risk of stroke in CEA in 30 days 3.1% vs 0.8%
- ✧ 5 yr risk of non-preoperative stroke was 3.1% & 11% (p < .0001)
- ✧ Carotid stenting / angioplasty (SAPHIRE) equivalent to CEA



Secondary Prevention



∞ Carotid revascularisation :

- Carotid endarterectomy

ECST & NASCET- 5893 pt 33000 pt-yr

- Benefit greater aged > 75 yrs

- Carotid stent

& SAPPHIRE : 3 yrs – absolute difference in stent
& CEA were 7.9%

- Yadav 2004

∞ Cholesterol

∞ Relationship is less understood

Incidence increase in highest total cholesterol : HDL ratio

HPS : 4.3 yrs after stroke – Simvastatin

After 4 yrs 20% risk reduction in vascular events.

Statin- in addition to lipid lowering action a) Upgrade NO synthase b) inhibit iNO c) attenuate inflammatory cytokines in cerebral ischaemia d) modify endothelial function, Arc Neurology 2005

Target level 100mg/dl(2.6mmol/L) Start 3.4mg/dl

Secondary Prevention (contd.)



- Small increase (2-6/ 1000) in hemorrhage is offset by reduction in vascular events 51/1000.

⌘ Homocysteine –considered as a risk factor-independent?


VISP (VITOPS) –B vitamins help in reduction

⌘ Antiplatelet

CURE / MATCH / CAPRIE

- Clopidogrel + Aspirin reduced RR of vascular event by 20% vs Aspirin alone.

Xime lagatrans-a thrombin inhibitor is better than warferin because it does not need regular INR check, JAMA 2005



CONCLUSION

- NOT WARNING- CONSIDER TIA AS STROKE
- CONSIDER FOR ACUTE TREATMENT
- WORK UP FOR SECONDARY PREVENTION



DILEMA IN TIA TREATMENT

- WHAT IS THE TREATMENT?
- INTERVENE
- WATCH
- TREATMENT FOR SECONDARY PREVENTION

